DEA Eases Requirements For FDA-Approved Clinical Trials On Cannabidiol
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • DEA Eases Requirements For FDA-Approved Clinical Trials On Cannabidiol

DEA Eases Requirements For FDA-Approved Clinical Trials On Cannabidiol

December 23, 2015
|
Share Article
|
Download Press Release
For Immediate Release
Contact: DEA Public Affairs
Phone Number: (571) 776-2508

WASHINGTON - The United States Drug Enforcement (DEA) recently eased some of the regulatory requirements imposed by the Controlled Substances (CSA) for those who are conducting FDA-approved clinical trials on (CBD), an extract of the marijuana plant.  These modifications will streamline the research process regarding CBD’s possible medicinal value and help foster ongoing scientific studies.  The DEA notified affected researchers by letter of the changes, which take effect immediately.  

Federal (21 CFR 1301.18) requires researchers conducting CBD-based clinical trials under an FDA Investigational New Drug Application to have a DEA research registration.  This registration permits the possession of an approved amount of CBD for a specific research protocol.  Prior to now, researchers who expanded the scope of their studies and needed more CBD than initially approved for had to request, in writing, a modification to their DEA research registrations - potentially delaying that research while the modification underwent an approval process that includes both the DEA and the Food and Drug (FDA).  Under these changes, a previously registered CBD clinical researcher who is granted a waiver can readily modify their protocol and continue their research seamlessly.  This waiver effectively removes a step from the approval process.

Marijuana is a Schedule I controlled substance because of the presence of , marijuana’s psychoactive ingredient.  Because CBD contains less than 1 percent THC and has shown some potential medicinal value, there is great interest in studying it for medical applications.  Currently, CBD is a Schedule I controlled substance as defined under the CSA.  Though the FDA approves drugs for medical use in the United States, the DEA regulates the handling of all controlled substances, including those being used by researchers to conduct studies.  

Download Press Release
Attachments
drug_of_abuse.pdf
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

@DEAHQ
  • Facebook
  • X
  • Email
  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster

United States Drug Enforcement Administration

Back
  • Who We Are
  • What We Do
  • Careers
  • Resources
Back
  • About
  • Mission
  • History
  • Divisions
  • DEA Museum
  • Wall of Honor
  • Contact Us
Back
  • Domestic Divisions
  • Foreign Divisions
  • Operational Divisions
Back
  • Submit a Tip
  • Extortion Scam
  • Public Affairs
  • Social Media Directory
Back
  • Forensic Sciences
  • Law Enforcement
  • Education and Prevention
  • Drug Information
  • News
  • Campaigns
Back
  • GUARDS
  • Forensic Sciences Policy
  • Forensic Science Organizations
  • Forensic Science Contact
Back
  • DEA Office of Training
  • El Paso Intelligence Center (EPIC)
  • Intelligence
  • Operations
Back
  • Office of Training Programs
Back
  • Administrative Law Judges
  • DEA Asset Forfeiture
  • Domestic Cannabis Suppression / Eradication Program
  • HIDTA
  • OCDETF
Back
  • Family Summit
  • Red Ribbon
  • Kiki and the History of Red Ribbon Week
  • Red Ribbon Toolkit - Resources For Your Community
  • DEA’s Family Summit
  • Operation Engage
  • Community Outreach
  • Just Think Twice
  • Campus Drug Prevention
  • Get Smart About Drugs
  • Operation Prevention
Back
  • Drug Policy
  • Drug Scheduling
  • The Controlled Substances Act
Back
  • Alerts
  • Press Releases
  • Most Wanted Fugitives
  • Stories
  • Events
  • Speeches
  • Testimony
Back
  • All Fugitives
Back
  • One Pill Can Kill
  • DEA National Prescription Drug Take Back Day
Back
  • Senior Citizens
  • Partner Toolbox
  • Social Media Campaign
Back
  • Special Agent
  • Diversion Investigator
  • Intelligence Research Specialist
  • Forensic Sciences Careers
  • Professional & Administrative Careers
  • Student & Entry Level Careers
  • Employment Eligibility
  • How to Apply
Back
  • Special Agent FAQs
Back
  • Diversion Investigator Job Announcement
Back
  • Intelligence Research Specialist Job Announcements
  • Intelligence Research Specialists FAQs
  • Schedule A Hiring Authority: Intelligence Research Specialist
Back
  • How To Claim Veterans' Preference
  • Priority Consideration
  • Benefits
  • Veterans and People With Disabilities
  • Operation Warfighter
Back
  • Illegal Online Pharmacies
  • OD Justice
  • Fentanyl Supply Chain
  • Pill Press Resources
  • Recovery Resources
  • Together for Families
  • Data and Statistics
  • FOIA
  • Publications
  • Media Galleries
  • Victim Witness Assistance Program
Back
  • Domestic Arrests
  • Staffing and Budget
Back
  • About FOIA
  • Contact DEA FOIA
  • Make a Request
  • What Happens After Making a Request
  • Requester Categories
  • Fees Charged
  • Fee Waiver
  • FOIA FAQ
  • FOIA Logs and Reports
  • FOIA Library
  • Additional FOIA Links
  • FOIA Exemptions
  • What Are Exclusions?
  • Privacy Act
  • Privacy Act Exemptions
  • Privacy Impact Assessment and Management Information Systems
Back
  • Victim Witness Assistance Program Resources
  • Human Trafficking Prevention
  • Submit A Tip +
  • Get Updates
  • Scam Alert
    • English
    • Español